Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

- Oral presentation highlighted at 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting - Blue Earth Diagnostics, a Bracco company and recognized leader in the development

Related Keywords

Germany ,Italy ,Boston ,Massachusetts ,United States ,Milan ,Lombardia ,United Kingdom ,Munich ,Bayern ,Phillip Kuo ,Scintomics Gmb ,Kostenloser Wertpapierhandel ,Davide Gauden ,Clare Gidley ,Mike Beyer ,Priscilla Harlan ,Study Group ,Drug Administration ,Sam Brown Inc ,Bracco Group ,Technical University Of Munich ,Nuclear Medicine ,Corporate Communications ,Society Of Nuclear Medicine ,University Of Arizona ,Molecular Imaging ,Annual Meeting ,Earth Diagnostics ,Prostate Specific Membrane Antigen Targeted ,Business Wire ,Medical Imaging ,Biomedical Engineering ,New Drug Application ,Chief Executive Officer ,Blue Earth ,Blue Earth Diagnostic ,Radiohybrid Prostate Specific Membrane Antigen ,Technical University ,Blue Earth Diagnostics ,Scintomics Gmbh ,Earth Diagnostic ,Bracco Imaging ,Interventional Radiology ,Cardiac Catheterization ,Magnetic Resonance Imaging ,Contrast Enhanced Ultrasound ,Blue Earth Therapeutics ,Director Marketing ,Blue ,Earth ,Iagnostics ,Nnounces ,Leader ,Reproducibility ,Results ,Rom ,Hase ,Spotlight ,Trial ,Investigational ,Maging ,Agent ,Hpsma ,Biochemical ,Recurrence ,Prostate ,Dancer ,